Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study

Nickel, Marius; Nickel, Cerstin; Kaplan, Patrick; Lahmann, Claas; Mühlbacher, Moritz; Tritt, Karin; Krawczyk, Jakub; Leiberich, Peter; Rother, Wolfhardt K.; Loew, Thomas H.

doi:10.1016/j.biopsych.2004.11.044

Cited by 165 publications

(105 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…76,77 An open-label study of 22 institutionalized, intellectually disabled adults treated with topiramate found improvements in challenging or maladaptive behavior. 78 A notable prospective open-label study found improvements in nonhallucinatory posttraumatic stress disorder symptoms with topiramate.…”

Section: Topiramatementioning

confidence: 99%

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

2007

View full text Add to dashboard Cite

Summary: Antiepileptic drugs (AEDs) are commonly utilized for nonepileptic conditions, including various psychiatric disorders and pain syndromes. Evidence for their benefit in these nonepileptic conditions varies widely among different drugs, but there is, in general, a paucity of published multicenter randomized double-blind trials. Variable levels of evidence suggest that lamotrigine and the vagal nerve stimulator have antidepressant properties. Carbamazepine, valproate, lamotrigine, and oxcarbazepine appear to have mood stabilizing properties while gabapentin, pregabalin, and tiagabine have anxiolytic benefits. Barbiturates, topiramate, and possibly phenytoin may precipitate or exacerbate depression. Underlying depression and anxiety symptoms may be exacerbated by levetiracetam, while psychotic symptoms have rarely been reported with topiramate, levetiracetam, and zonisamide. Pregabalin, gabapentin, carbamazepine, and oxcarbazepine have been used to treat neuropathic pain such as postherpetic neuralgia, and diabetic polyneuropathy. Topiramate and divalproex sodium have utility in the prophylaxis or acute treatment of migraine. Further rigorous studies are needed to clarify the utility of AEDs in nonepileptic conditions.

show abstract

Section: Topiramatementioning

confidence: 99%

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

2007

View full text Add to dashboard Cite

show abstract

“…9 Initially, complex epilepsy was the only indication for treatment with topiramate. Recently it has been suggested that topiramate may be useful in the treatment of obesity [10][11][12][13][14][15] , eating disorders [16][17][18][19][20] , migraine [21][22][23][24][25][26][27][28][29][30][31] , bipolar disorders [32][33][34][35] , other psychiatric disorders [36][37][38][39][40][41][42] , alcohol dependence [43][44][45][46][47] and other addictive disorders 48 . Also the drug is more frequently used in the management of childhood epilepsy [49][50][51] .…”

Section: Introductionmentioning

confidence: 99%

Retinal function and histopathology in rabbits treated with Topiramate

et al. 2006

View full text Add to dashboard Cite

Methods: Six rabbits were treated with a daily oral dose of topiramate orally during a period of eight months. Six rabbits receiving water served as controls. Blood samples were analyzed for determination of topiramate serum levels in order to ensure successful drug exposition.Standardized full-field electroretinograms (ERGs) were performed before treatment and then at 2, 3 and 8 months during the treatment period. After terminating treatment the rabbits were sacrificed and the morphology of the sectioned retina was studied. The retinal dysfunction and the morphological changes indicate that topiramat may damage the retina, similarly to vigabatrin (another anti-epileptic drug).

show abstract

“…Topiramate was superior to placebo with respect to most of the StateTrait Anger Expression Inventory (STAXI) scales. The second topira mate RCT by the same group [32] included 42 male patients and obtained approximately the same results.…”

Section: Valproatementioning

confidence: 62%

Recent approaches to pharmacotherapy of personality disorders

Bellino

Rinaldi²,

Bozzatello³

et al. 2011

Neuropsychiatry

View full text Add to dashboard Cite

Recent approaches to pharmacotherapy of personality disorders Practice pointsPharmacotherapy of personality disorders should be considered a symptom-focused treatment, targeting dimensions of affective dysregulation, impulsive-behavioral dyscontrol and cognitive-perceptual symptoms.To date, randomized controlled trials have been performed in samples of patients with antisocial personality disorder, schizotypal personality disorder and borderline personality disorder (BPD). However, the great majority of these trials have been conducted in samples with BPD.There is some evidence that mood stabilizers (topiramate, valproate and lamotrigine), second-generation antipychotics (olanzapine, aripiprazole), and omega-3 fatty acids can be useful for the treatment of affective symptoms and impulsive-behavioral dyscontrol in BPD patients.Antipsychotics produced an improvement of psychotic-like symptoms both in patients with BPD and schizotypal personality disorder.Selective serotonin reuptake inhibitors were found to be effective in decreasing depressed mood, anxiety, and anger in BPD patients, mainly with a comorbid major depressive episode. However, recent evidence no longer supports their use as first-line treatment of affective symptoms and impulsive-behavioral dyscontrol in BPD.Present studies suffer from important methodological limitations. Thus, further investigations are needed to confirm available findings. SUMMARY A growing number of studies on pharmacotherapy of personality disorders have been performed. This article considers controlled trials conducted between 1990 and 2010, and is directed toward the treatment of personality disorders. Data on borderline personality disorder (BPD), antisocial personality disorder and schizotypal personality disorder (STPD) were collected and discussed, in order to provide indications for clinical practice. Concerning antisocial personality disorder and STPD, available evidence is too sparse to propose treatment recommendations. As for BPD, there is some evidence that mood stabilizers (topiramate, valproate, and lamotrigine), second-generation antipsychotics (olanzapine, aripiprazole), and omega-3 fatty acids can be useful to treat affective symptoms For reprint orders, please contact: reprints@futuremedicine.comNeuropsychiatry (2011) 1(3) future science group 260Review Bellino, Rinaldi, Bozzatello & Bogetto Personality disorders (PDs) are defined as endur ing patterns of inner experience and behavior causing distress, which lead to maladaptive functioning in the areas of emotion, cognition, interpersonal relationships and impulse con trol [1]. Since the 1980s there has been increas ing recognition that PDs can be considered as syndromes of interacting dimensional traits that arise from psychosocial development and/or biological vulnerability [2]. Personality dimen sions acquired through social and cultural learning are termed character, whereas those believed to have a biological origin, genetically determined or acquired from overt injury to the CNS, are traditionally referr...

show abstract

Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study

Cited by 165 publications

References 18 publications

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

Use of Antiepileptic Drugs for Nonepileptic Conditions: Psychiatric Disorders and Chronic Pain

Retinal function and histopathology in rabbits treated with Topiramate

Recent approaches to pharmacotherapy of personality disorders

Contact Info

Product

Resources

About